최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기생명과학회지 = Journal of life science, v.21 no.6 = no.134, 2011년, pp.912 - 922
김미희 (부산대학교 의학전문대학원 생화학교실) , 송명하 (부산대학교 의학전문대학원 생화학교실) , 이상률 (부산대학교 의학전문대학원 생화학교실)
Cancer-testis (CT) antigens are immunogenic protein antigens with restricted expression in the testes and a wide range of human tumor types, eliciting both humoral and cellular immune responses in cancer patients. They are considered to be ideal targets for vaccine-based immunotherapy, and more than...
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
현재까지 동정된 CT antigen은 어떠한 것들이 있는가? | Cancer-testis (CT) antigen은 다양한 종양과 정상 고환에서 제한적으로 발현되고, 암환자에서 체액성 면역과 세포성 면역반응을 일으키는 종양항원이다. 지금까지 MAGE, NY-ESO-1, GAGE, BAGE, LAGE, SSX2, NY-SAR-35를 포함하여 100개 이상의 CT antigen들이 동정되었고, 이러한 CT antigen들은 백신을 이용한 면역치료에 있어서 중요한 요소로 작용할 것으로 사료된다. CT antigen은 여러 가지 방법들을 통해 확인할 수 있고, X 염색체에 암호화 되어있는 CT-X gene과 X 염색체에 암호화 되어있지 않은 non-X CT gene으로 나눌 수 있다. | |
CT antigens란 무엇인가? | CT antigens은 정상 고환과 여러 다른 종양에서 발현되는 종양 항원의 일종이다. 그들의 이름에서 암시하듯 그들의 발현은 고환의 생식 세포에서 나타난다. | |
SEREX 접근법의 특징은 무엇인가? | SEREX 접근법은 다음과 같은 특징을 가진다. 첫 번째 in vivo에서 암세포에 의해 발현되는 유전자를 분석하기 위해서 신선한 암 조직 표본을 사용해야 한다. 두 번째 환자 혈청의 사용으로 여러 항원을 확인할 수 있다. 세 번째 스크리닝은 높은 역가의 항체반응을 나타내는 항원에 제한적이다. |
Akers, S. N., K. Odunsi, and A. R. Karpf. 2010. Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol. 6, 717-732.
Bai, S., B. He, and E. M. Wilson. 2005. Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction. Mol. Cell Biol. 25, 1238-1257.
Boel, P., C. Wildmann, M. L. Sensi, R. Brasseur, J. C. Renauld, P. Coulie, T. Boon, and P. van der Bruggen. 1995. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2, 167-175.
Caballero, O. L. and Y. T. Chen. 2009. Cancer?testis (CT) antigens: Potential targets for immunotherapy. Cancer Sci. 100, 2014-2021.
Chen, Y. T., A. O. Gure, S. Tsang, E. Stockert, E. Jager, A. Knuth, and L. J. Old. 1998. Identification of multiple cancer?testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc. Natl. Acad. Sci. USA 95, 6919-6923.
Chen, Y. T., M. J. Scanlan, U. Sahin, O. Tureci, A. O. Gure, S. Tsang, B. Williamson, E. Stockert, M. Pfreundschuh, and L. J. Old. 1997. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94, 1914-1918.
Chen, Y. T., M. J. Scanlan, C. A. Venditti, R. Chua, G. Theiler, B. J. Stevenson, C. Iseli, A. O. Gure, T. Vasicek, R. L. Strausberg, C. V. Jongeneel, L. J. Old, and A. J. Simpson. 2005. Identification of cancer?testis antigen genes by massively parallel signature sequencing. Proc. Natl. Acad. Sci. USA 102, 7940-7945.
Chomez, P., O. De Backer, M. Bertrand, E. De Plaen, T. Boon, and S. Lucas. 2001. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 61, 5544-5551.
Duan, Z., Y. Duan, D. E. Lamendola, R. Z. Yusuf, R. Naeem, R. T. Penson, and M. V. Seiden. 2003. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin. Cancer Res. 9, 2778-2785.
Fratta, E., S. Coral, A. Covre, G. Parisi, F. Colizzi, R. Danielli, H. J. Marie Nicolay, L. Sigalotti, and M. Maio. 2011. The biology of cancer testis antigens: Putative function, regulation and therapeutic potential. Mol. Oncol. 5, 164-182
Gaugler, B., B. Van den Eynde, P. van der Bruggen, P. Romero, J. J. Gaforio, E. De Plaen, B. Lethe, F. Brasseur, and T. Boon. 1994. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179, 921-930.
Ghafouri-Fard, S. and M. H. Modarressi. 2009. Cancer-testis antigens: potential targets for canceri. Arch. Iran. Med. 12, 395-404.
Gure, A. O., E. Stockert, K. C. Arden, A. D. Boyer, C. S. Viars, M. J. Scanlan, L. J. Old, and Y. T. Chen. 2000. CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representationaldifference analysis. Int. J. Cancer 85, 726-732.
Harada, N., K. Hoshiai, Y. Takahashi, Y. Sakaguchi, T. Kuno, T. shida, and H. Shiku. 2008. Preclinical safety pharmacology study of a novel protein-based cancer vaccine CHP-NY-ESO-1. Kobe. J. Med. Sci. 54, E23-34.
Jager, E., J. Karbach, S. Gnjatic, A. Neumann, A. Bender, D. Valmori, M. Ayyoub, E. Ritter, G. Ritter, D. Jager, D. Panicali, E. Hoffman, L. Pan, H. Oettgen, L. J. Old, and A. Knuth. 2006. Recombinant vaccinia ? fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc. Natl. Acad. Sci. USA 103, 14453-14458.
Jungbluth, A. A., W. A. Silva Jr, K. Iversen, D. Frosina, B. Zaidi, K. Coplan, S. K. Eastlake-Wade, S. B. Castelli, G. C. Spagnoli, L. J. Old, and M. Vogel. 2007. Expression of cancer- testis (CT) antigens in placenta. Cancer Immun. 7, 15-29.
Kaneda, A., T. Tsukamoto, T. Takamura-Enya, N. Watanabe, M. Kaminishi, T. Sugimura, M. Tatematsu, and T. Ushijima. 2004. Frequent hypomethylation in multiple promoter CpG islands is associated with global hypomethylation, but not with frequent promoter hypermethylation. Cancer Sci. 95, 58-64.
Lee, S. Y., Y. Obata, M. Yoshida, E. Stockert, B. Williamson, A. A. Jungbluth, Y. T. Chen, L. J. Old, and M. J. Scanlan. 2003. Immunomic analysis of human sarcoma. Proc. Natl. Acad. Sci. USA 100, 2651-2656.
Lehmann, F, L. J., S. Gaulis, O. Gruselle, and V. Brichard. 2008. Clinical response to the MAGE-A3 immunotherapeutic in metastatic melanoma patients is associated with a specific gene profile present prior to treatment. XVIth meeting in the cancer research institute international cancer immunotherapy symposium series and the 2008 meeting of the cancer vaccine consortium. New York City. S25.
Madsen, B., M. Tarsounas, J. M. Burchell, D. Hall, R. Poulsom, and J. Taylor-Papadimitriou. 2003. PLU-1, a transcriptional repressor and putative testis-cancer antigen, has a specific expression and localisation pattern during meiosis. Chromosoma 112, 124-132.
Manning, A. T., J. T. Garvin, R. I. Shahbazi, N. Miller, R. E. McNeill, and M. J. Kerin. 2007. Molecular profiling techniques and bioinformatics in cancer research. Eur. J. Surg. Oncol. 33, 255-265.
Marchand, M., N. van Baren, P. Weynants, V. Brichard, B. Dreno, M. H. Tessier, E. Rankin, G. Parmiani, F. Arienti, Y. Humblet, A. Bourlond, R. Vanwijck, D. Lienard, M. Beauduin, P. Y. Dietrich, V. Russo, J. Kerger, G. Masucci, E. Jager, J. De Greve, J. Atzpodien, F. Brasseur, P. G. Coulie, P. van der Bruggen, and T. Boon. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80, 219-230.
Meklat, F., Z. Li, Z. Wang, Y. Zhang, J. Zhang, A. Jewell, and S. H. Lim. 2007. Cancer-testis antigens in haematological malignancies. Br. J. Haematol. 136, 769-776.
Mischo, A., B. Kubuschok, K. Ertan, K. Preuss, B. Romeike, E. Regitz, E. Regitz, C. Schormann, D. de Bruijn, A. Wadle, F. Neumann, W. Schmidt, C. Renner, and M. Pfreundschuh. 2006. Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int. J. Cancer 118, 696-703.
Nagao, T., H. Higashitsuji, K. Nonoguchi, T. Sakurai, S. Dawson, R. J. Mayer, K. Itoh, and J. Fujita. 2003. MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J. Biol. Chem. 278, 10668-10674.
Nicholaou, T., L. M. Ebert, I. D. Davis, G. A. McArthur, H. Jackson, N. Dimopoulos, B. Tan, E. Maraskovsky, L. Miloradovic, W. Hopkins, L. Pan, R. Venhaus, E. W. Hoffman, W. Chen, and J. Cebon. 2009. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine inpatients with advanced malignant melanoma. Clin. Cancer Res. 15, 2166-2173.
Old, L. J. and Y. T. Chen. 1998. New paths in human cancer serology. J. Exp. Med. 187, 1163-1167.
Ollinger, R., M. Alsheimer, and R. Benavente. 2005. Mammalian protein SCP1 forms synaptonemal complex-like structures in the absence of meiotic chromosomes. Mol. Biol. Cell 16, 212-217.
Ross, M. T., D. V. Grafham, A. J. Coffey, S. Scherer, K. McLay, D. Muzny, and et al. 2005. The DNA sequence of the human X chromosome. Nature 434, 325-337.
Sahin, U., O. Tureci, Y. T. Chen, G. Seitz, C. Villena-Heinsen, L. J. Old, and M. Pfreundschuh. 1998. Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. Int. J. Cancer 78, 387-389.
Sahin, U., O. Tureci, and M. Pfreundschuh. 1997. Serological identification of human tumor antigens. Curr. Opin. Immunol. 9, 709-716.
Sahin, U., O. Tureci, H. Schmitt, B. Cochlovius, T. Johannes, R. Schmits, F. Stenner, G. Luo, I. Schobert, and M. Pfreundschuh. 1995. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA 92, 11810-11813.
Scanlan, M. J., A. O. Gure, A. A. Jungbluth, L. J. Old, and Y. T. Chen. 2002. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188, 22-32.
Simpson, A. J., O. L. Caballero, A. Jungbluth, Y. T. Chen, and L. J. Old. 2005. Cancer-testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 5, 615-625.
Sugita, M., M. Geraci, B. Gao, R. L. Powell, F. R. Hirsch, G. Johnson, R. Lapadat, E. Gabrielson, R. Bremnes, P. A. Bunn, and W. A. Franklin. 2002. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res. 62, 3971-3979.
Tajima, K., Y. Obata, H. Tamaki, M. Yoshida, Y. T. Chen, M. J. Scanlan, L. J. Old, H. Kuwano, T. Takahashi, T. Takahashi, and T. Mitsudomi. 2003. Expression of cancer/ testis (CT) antigens in lung cancer. Lung Cancer 42, 23-33.
Tanaka, R., T. Ono, S. Sato, T. Nakada, F. Koizumi, K. Hasegawa, K. Nakagawa, H. Okumura, T. Yamashita, M. Ohtsuka, K. Asagoe, O. Yamasaki, Y. Noguchi, K. Iwatsuki, and E. Nakayama. 2004. Over-expressin of the testis-specific gene TSGA10 in cancers and its immunogenicity. Microbiol. Immunol. 48, 339-345.
Van den Eynde, B., O. Peeters, O. De Backer, B. Gaugler, S. Lucas, and T. Boon. 1995. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182, 689-698.
Van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647.
Van Pel, A., P. van der Bruggen, P. G. Coulie, V. G. Brichard, B. Lethe, B. van den Eynde, C. Uyttenhove, J. C. Renauld, and T. Boon. 1995. Genes coding for tumour antigens recognized by cytolytic T lymphocytes. Immunol. Rev. 145, 229-250.
Wadle, A., B. Kubuschok, J. Imig, B. Wuellner, C. Wittig, C. Zwick, A. Mischo, K. Waetzig, B. Romeike, W. Lindemann, M. Schilling, M. Pfreundschuh, and C. Renner. 2006. Serological immune responses to cancer testis antigens in patients with pancreatic cancer. Int. J. Cancer 119, 117-125.
Yokoe, T., F. Tanaka, K. Mimori, H. Inoue, T. Ohmachi, M. Kusunoki, and M. Mori. 2008. Efficient identification of a novel cancer/testis antigen for immunotherapy using three-step microarray analysis. Cancer Res. 68, 1074-1082.
Yuan, J., S. Gnjatic, H. Li, S. Powel, H. F. Gallardo, E. Ritter, G. Y. Ku, A. A. Jungbluth, N. H. Segal, T. S. Rasalan, G. Manukian, Y. Xu, R. A. Roman, S. L. Terzulli, M. Heywood, E. Pogoriler, G. Ritter, L. J. Old, J. P. Allison, and J. D. Wolchok. 2008. CTLA-4 blockade enhances polyfunctional NYESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl. Acad. Sci. USA 105, 20410-20415.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.